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Abstract
Inclusion complexation between β-cyclodextrin (β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD), water-soluble poly-
mers (PVP and HPMC) and vinpocetine was studied in aqueous solution and in the solid state. Phase solubility studies
were used to evaluate the complexation in aqueous solution at room temperature. Stability constants (Kc) of binary and
ternary complexes were determined spectrophotometrically. Differential scanning calorimetry (DSC) was used to char-
acterize kneaded, co-evaporated and lyophilised binary and ternary systems. The Kc values obtained were 70.14 M−1
and 35.01 M−1 for vinpocetine-β-CD and vinpocetine-HP-β-CD and increased in a range of 17% to 94% by addition of
water-soluble polymers. Some preliminary evidences of inclusion complexation were obtained from DSC suggesting that
co-evaporated and lyophilised binary and ternary systems were truly inclusion complexes.
Introduction
Cyclodextrins (CDs) are typical host molecules known for
forming inclusion complexes with many guest molecules in-
cluding lipophilic drugs, affecting their physical and chem-
ical properties, such as solubility and stability [1]. Unfor-
tunately, the efficiency complexation of drugs by CDs is
rather low and consequently a significant amount of CDs
is needed to solubilise a small quantity of drug. Besides,
many vehicles additives commonly used in drug formula-
tion such as non-ionic surfactants, buffer salts, preservatives
and organic solvents contribute even more for the reduced
efficiency complexation [2].
For those reasons associated with toxicological consider-
ations, formulation bulk and production costs it is important
to use as little CDs as possible in pharmaceutical prepara-
tions. Thus, it is therefore imperative to develop methods
that can be applied to enhance the complexation efficiency of
CDs, such as the addition of small amounts of water-soluble
polymers to aqueous CD solution, along with heating [3].
The aim of this work was to examine the potential
of β-CD and HP-β-CD in association with water-soluble
polymers as solubilizing agents for vinpocetine, a poorly
water-soluble base-type drug with significant peripheral vas-
odilator effect [4] using the phase solubility study technique
and characterize the complexes formed by DSC.
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Materials and methods
Chemicals
β-CD (Lot 341001; MW 1135) and HP-β-CD (Lot
955477D; TDS 6.3; MW 1300) were a gift from Roquette
Vinpocetine (Lot CV/VP010701; MW 350.46) was pur-
chased from Covex (Madrid, Spain). Polyvinylpyrrolidone
K30 (PVP), HPMC 4000 cps and tartaric acid were supplied
by Sigma Chemical Co. (St. Louis, USA).
Phase solubility studies
Phase solubility studies in deionised water at room temperat-
ure (22 ± 1 ◦C) were carried out for both binary and ternary
systems according to the method of Higuchi and Connors
[5]. Excess amounts of vinpocetine base were weighted into
20 ml glass flasks to which were added 10 ml of aqueous
solutions containing increasing amounts of β-CD (0.001–
0.015 M or 0.001–0.028 M in the presence of polymers)
or HP-β-CD (0.001–0.08 M), with or without a fixed poly-
mer concentration of 0.25% (W/V) PVP and 0.1% (W/V)
HPMC.
In binary systems, glass containers were sealed and
mechanically stirred until reaching equilibrium (about 72
hours). In the case of ternary systems, glass containers were
sealed and heated in an autoclave at 120 ◦C for 20 minutes
and then allowed to equilibrate for 72 hours.
All suspensions were filtered through a 0.45 µm mem-
brane filter (Millipore) and analysed spectrophotometrically
(UV-1603, Shimadzu) at 316 nm for drug content. To nul-
lify the absorbance due to the presence of cyclodextrins and
polymers, the apparatus were calibrated with the corres-
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ponding blank every assay. Three replicates have been made
for each experiment.
The apparent stability constants (Kc) were estimated
from the straight line of the phase solubility diagrams
according to the following equation of Higuchi and Connors:
Kc = slope/intercept (1 − slope)
Preparation of vinpocetine binary and ternary solid systems
Solid systems were prepared with equimolar ratio of vin-
pocetine and cyclodextrins using three distinct methods:
kneading, co-evaporation and freeze-drying.
Physical binary and ternary mixtures
Physical mixtures of vinpocetine with cyclodextrins (β-CD
and HP-β-CD) were prepared by previously sieving each
component (75–100 µm) and subsequently by mixing them
in a ceramic mortar for 5 minutes.
For ternary physical mixtures were added 15% (W/W)
of PVP and 6% (W/W) of HPMC. They were also pre-
pared, following the same procedure, physical mixtures with
equimolar amounts of tartaric acid:vinpocetine from binary
and ternary physical mixtures previously described.
All mixing procedures were performed adopting the
geometric method.
Kneaded binary and ternary
Kneaded systems were prepared from physical binary and
ternary mixtures by adding a small volume of 17% (W/V)
tartaric acid solution equivalent to the 1:1 molar ratio vin-
pocetine:tartaric acid. After wetting the physical mixtures
in a ceramic mortar, the resultant systems were vigorously
kneaded with a pestle for 30 minutes to produce a homogen-
eous dispersion. Once homogeneous slurry was obtained,
samples where dried at 40 ◦C for 48 hours.
Co-evaporated binary systems
0.571 mmol of cyclodextrin (β-CD or HP-β-CD) was dis-
solved in 50 ml of deionised water and 0.571 mmol of
vinpocetine in 10 ml of 1.5% (W/V) tartaric acid solution.
The two solutions were subjected to stirring (100 rpm) at
60 ◦C for three hours and the obtained clear solution was
evaporated under vacuum at 50 ◦C in a rotatory evaporator
(Heidolph, Laborota). The solid residue was further dried at
40 ◦C for 48 hours.
Co-evaporated ternary systems
0.571 mmol of cyclodextrin (β-CD or HP-β-CD) was dis-
solved in 50 ml of a 0.25% (W/V) of PVP solution or 0.1%
(W/V) of a HPMC solution and 0.571 mmol of vinpocet-
ine in 10 ml of 1.5% (W/V) tartaric acid solution. The
two solutions were mixed and subjected to sonication in
an ultrasound water-bath for 15 minutes and then heated in
an autoclave (Uniclave 88) at 120 ◦C for 20 minutes. The
resultant clear solution was allowed to equilibrate at room
temperature for 72 hours and then evaporated under vacuum
at 50 ◦C in a rotatory evaporator (Heidolph, Laborota). The
solid residue was further dried at 40 ◦C for 48 hours.
Lyophilised binary systems
0.571 mmol of cyclodextrin (β-CD or HP-β-CD) was dis-
solved in 50 ml of deionised water and 0.571 mmol of
vinpocetine in 10 ml of 1.5% (W/V) tartaric acid solu-
tion. The two solutions were sonicated for 15 minutes in
an ultrasound water-bath and mixed for 2 at 50 ◦C. Finally,
the resultant clear solution was frozen by immersion in an
ethanol bath (Shell Freezer, Labconco, Freezone model
79490) at −50 ◦C. After that, frozen solutions were lyophil-
ised in a freeze-dryer (Lyph-lock 6 apparatus, Labconco) for
three days.
Lyophilised ternary systems
0.571 mmol of cyclodextrin (β-CD or HP-β-CD) was dis-
solved in 50 ml of a 0.25% (W/V) of PVP solution or 0.1%
(W/V) of a HPMC solution and 0.571 mmol of vinpocetine
in 10 ml of 1.5% (W/V) tartaric acid solution. The two solu-
tions were mixed and subjected to sonication for 15 minutes
in an ultrasound water-bath and then heated in an auto-
clave (Uniclave 88) at 120 ◦C for 20 minutes. The resultant
clear solution was allowed to equilibrate at room temperat-
ure for 72 hours and subsequently frozen by immersion in
an ethanol bath (Shell Freezer,Labconco, Freezone model
79490) at −50 ◦C. Finally, frozen solutions were submitted
to lyophilization in a freeze-dryer (Lyph-lock 6 apparatus,
Labconco) for three days. All resultant dried systems were
crushed and sieved, and fractions smaller than 100 µm were
collected for further studies.
Differential scanning calorimetry (DSC)
The DSC curves of pure materials, binary and ternary sys-
tems were recorded on a Shimadzu DSC-50 System with
a DSC equipped with a computerized data station TA-
50WS/PC. The thermal behaviour was studied by heating
all accurately weighted samples (1 mg of vinpocetine or
its equivalent) in a sealed aluminium pan, using an empty
pan sealed as reference, over the temperature range of 30–
400 ◦C, at a rate of 10 ◦C/minute and under a nitrogen flow
of 20 cm3/minute.
Indium (99.98%, m.p. 156.65 ◦C, Aldrich, Mil-
wauukee, USA) was used as standard for calibrating the




The influence of CD concentration in the presence or ab-
sence of water-soluble polymers on the solubility of vin-
pocetine was studied using the method of Higuchi and
Connors. This is based on monitoring changes in the sol-
ubility of a substrate by the addition of complexing agents
assayed, in this case, spectrophotometrically at 316 nm.
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Figure 1. Phase solubility diagrams for vinpocetine at room temperature in the presence of β-CD (A) and HP-β-CD (B) without water-soluble polymers
() and with 0.25% (W/V) PVP () or 0.1% (W/V) HPMC (). Each point is the mean of (±SD) of three determinations.
Figure 2. Vinpocetine solubility by complexation in 16 mM aqueous solu-
tion of β-CD and in 80 mM aqueous solution of HP-β-CD () without
polymers and in presence of 0.25% (W/V) PVP () or 0.1% (W/V) HPMC
( ).
The phase-solubility studies diagrams obtained with
both CDs (β-CD and HP-β-CD) with and without water-
soluble polymers (PVP and HPMC) are shown in Figure 1.
They displayed AL type (Higuchi and Connors) equilib-
rium phase solubility diagrams for Vinpocetine:β-CD and
Vinpocetine:HP-β-CD binary and ternary systems, showing
that vinpocetine solubility increase linearly as a function of
CD concentration and that soluble complexes were formed
without occurrence of precipitation in the range of CD
concentration used.
The slope values were in all diagrams less than one
suggesting the formation of 1:1 stoichiometry complexes
in solution and allowing to the calculation of the apparent
stability constants (Kc) of the drug:CD complexes as from
the Higuchi and Connors equation. The values of the appar-
ent stability constants of vinpocetine:CD binary and ternary
complexes are collected in Table 1.
As can be seen, addition of water-soluble polymers to
the CD solution did not change the type of phase-solubility
diagrams obtained for binary systems and always resulted
in a Kc increase that varied from a minimum of 17% to a
maximum of 94%, depending on the CD and water-soluble
polymer considered. The observed enhancement of Kc upon
addition of the polymers shows that the polymers are able
to interact with drug-CD binary complexes [6]. The sol-
ubilizing effect of CDs was increased in the presence of
both 0.25% (W/V) PVP and 0.1% (W/V) HPMC being
particularly this one remarkably effective in increasing the
solubilizing effect of β-CD and HP-β-CD. Consequently, a
synergistic effect in vinpocetine solubility was observed in
the presence of CDs and those water-soluble polymers after
heating in an autoclave at 120 ◦C for 20 minutes. Moreover,
the presence of polymers changed the β-CD concentration
range making possible an increase on vinpocetine solubility
under a wider range of β-CD concentration (0–28 mM). The
vinpocetine solubility enhancement after complexation with
CDs and polymers is represented in Figure 2.
Interestingly, it was also demonstrated that
vinpocetine:β-CD binary and ternary systems were more
stable than those with HP-β-CD, probably because the
subsistent hydroxypropyl groups of HP-β-CD hamper the
inclusion of guest molecules into CD cavity via steric
hindrance [7].
Differential scanning calorimetry
Differential scanning calorimetry (DSC) represents a first
choice analytical tool for an accurate physicochemical char-
acterization of drug-CD systems in the solid state and is
commonly used as a routine method for a rapid prelimin-
ary qualitative investigation of the thermal behaviour of the
single components, their physical mixtures and the inclu-
sion compound candidate prepared according to a variety
of standard procedures (e.g., kneading, co-evaporation and
freeze-drying). The purpose consists of providing evid-
ence that differences between the physical mixtures and the
putative inclusion complex exist [8].
The DSC profiles of pure components and of the re-
spective binary and ternary systems prepared by different
methods in the melting range of the drug and dehydration of
the carrier are shown in Figures 3 and 4. The thermal curve
of pure vinpocetine was typical of a crystalline anhydrous
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Figure 3. Differential scanning calorimetry curves of vinpocetine (Vinpo), β-cyclodextrin (β-CD), water-soluble polymers (PVP and HPMC), binary
and ternary systems containing them: physical mixtures (PM), physical mixtures with tartaric acid in equimolar amount (PM + Ac), kneaded (KN),
co-evaporated (COE) and lyophilised (LpH) products.
Table 1. Values of Kc for binary and ternary complexes; KTS/KBS is the ratio of Kc
for binary and ternary complexes
Polymer β-CD HP-β-CD
Kc (M−1) KTS/KBS Kc (M−1) KTS/KBS
No polymer 70.14 – 35.01 –
0.25% (W/V) PVP 102.00 1.45 41.10 1.17
0.1% (W/V) HPMC 136.41 1.94 60.60 1.73
substance with a sharp endothermic peak at 149.3 ± 0.6 ◦C
corresponding to the melting point of the drug. The DSC
curve of β-CD showed the liberation of crystal water as an
endothermal effect peaked at about 135 ◦C, whereas broader
endotherms were associated with water loss from amorphous
HP-β-CD, PVP and HPMC.
The comparison of DSC curves from binary systems
with those belonging to ternary systems did not result in
significant differences. Both characteristics peaks of vin-
pocetine (drug melting) and CDs (water loss) were clearly
distinguishable in binary and ternary physical mixtures, be-
ing the DSC thermograms of those the superposition of
the individual components. Concerning the binary and tern-
ary physical mixtures with addition of tartaric acid, the
thermal characteristic peak of vinpocetine was shifted to
lower temperatures at around 146.0–147.9 ◦C and its intens-
ity was reduced. Those little changes relative to the peak of
pure vinpocetine may suggest a weak interaction between
the components of the physical mixtures with tartaric acid
during the mixing or heating for DSC scanning [9–10].
Oppositely, the complete disappearance of the drug en-
dothermal effect was observed in all binary and ternary
systems obtained by kneading, co-evaporation and lyophiliz-
ation. This phenomenon, thought not unequivocally attribut-
able to inclusion complex formation is however undoubtedly
indicative of a stronger interaction in the solid state [11–12]
between vinpocetine, CDs, tartaric acid and water-soluble
polymers when those are manipulated by the procedures
previously described.
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Figure 4. Differential scanning calorimetry curves of vinpocetine (Vinpo), β-cyclodextrin (β-CD), water-soluble polymers (PVP and HPMC), binary
and ternary systems containing them: physical mixtures (PM), physical mixtures with tartaric acid in equimolar amount (PM + Ac), kneaded (KN),
co-evaporated (COE) and lyophilised (LpH) products.
Conclusions
As reported previously by other authors [3, 13], water-
soluble polymers increase the solubilizing effect of cyclo-
dextrins, in aqueous solutions, on various hydrophobic drugs
by increasing Kc of the drug-CD complexes. This increase
enhances the complexation efficiency and thus less cyclo-
dextrin is needed to solubilise a given amount of drug when
polymers are present in the aqueous media.
Specifically in this work, the addition of polymers to
cyclodextrin solutions made the slope of the solubility iso-
therms emphasized and in agreement with previous reports
[14–16] the resultant ternary systems showed higher stabil-
ity constants than the binary vinpocetine-CDs complexes,
which account for the enhancement on vinpocetine solubil-
ity. Furthermore, the total solubility of β-CD was enhanced
by addition of small amounts of polymers by increase in both
β-CD intrinsic solubility and in aqueous solubility of the
resulting complexes. There, the polymers not only increase
the βCD intrinsic solubility but also enhanced its complexa-
tion efficiency [6]. By the fact of the absolute disappearance
of vinpocetine endothermal effect in kneaded, co-evaporated
and lyophilised binary and ternary products, solid-state char-
acterization by DSC suggests that they are strong evidences
for these products being true inclusion compounds.
These observations and other experimental data, as yet
not published, indicate that the polymers participate dir-
ectly in the complexation under the formation of drug-CD-
polymer complexes.
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